| Title |
Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2017
|
| DOI | 10.2147/dddt.s110131 |
| Pubmed ID | |
| Authors |
Solomon A Graf, Jose M Garcia |
| Abstract |
Cancer anorexia-cachexia syndrome (CACS) is a complex and largely untreatable paraneoplastic complication common in advanced cancer. It is associated with profoundly deleterious effects on quality of life and survival. Since its discovery over a decade ago, anamorelin hydrochloride (anamorelin), a mimetic of the growth hormone secretagogue ghrelin, has shown considerable promise in ameliorating components of CACS when administered to patients with advanced cancer, including loss of lean body mass and reversal of anorexia. This review summarizes the development of anamorelin and its safety and efficacy in clinical investigations. The potential future role of anamorelin in treating CACS is also discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 14% |
| Other | 5 | 12% |
| Student > Doctoral Student | 4 | 9% |
| Professor > Associate Professor | 3 | 7% |
| Researcher | 3 | 7% |
| Other | 4 | 9% |
| Unknown | 18 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 21% |
| Agricultural and Biological Sciences | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Business, Management and Accounting | 1 | 2% |
| Other | 6 | 14% |
| Unknown | 20 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2017.
All research outputs
#17,350,971
of 25,461,852 outputs
Outputs from Drug Design, Development and Therapy
#1,108
of 2,272 outputs
Outputs of similar age
#209,910
of 327,733 outputs
Outputs of similar age from Drug Design, Development and Therapy
#32
of 47 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,272 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,733 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.